Treatment of mCRPC

Management of castrate resistant prostate cancer-recent advances and optimal sequence of treatments - Abstract

Published on Friday, 17 May 2013 20:20

Until 2010, chemotherapy with docetaxel was the only approved agent for treatment of metastatic castrate resistant prostate cancer (mCRPC).

A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases - Abstract

Published on Friday, 17 May 2013 07:10

Background: Cabozantinib is an oral MET/VEGFR2 inhibitor.

FDA approves new drug for advanced prostate cancer

Published on Wednesday, 15 May 2013 12:02

BERKELEY, CA USA (Press Release) - May 15, 2013 -

Xofigo approved three months ahead of schedule under priority review program

AUA 2013 - Session Highlights: Abiraterone shows improvement in quality of life outcomes at > 2 years of follow-up

Published on Monday, 13 May 2013 18:19

SAN DIEGO, CA USA (UroToday.com) - The emergence of several new agents that prolong survival for men with metastatic castrate resistant prostate cancer (mCRPC) has resulted in a fast-paced revolution of the advanced prostate cancer space.

Four new drugs on the market: Abiraterone, belatacept, vandetanib and fidaxomycine - Abstract

Published on Friday, 10 May 2013 15:22

Among the 35 new molecular entities approved by the FDA in 2011, 17 were particularly notable for their significant contributions to the health of patients, including abiraterone acetate, vandetanib, belatacept and fidaxomicin.

Variations in circulating sex steroid levels in metastatic prostate cancer patients with combined androgen blockade: Observation and implication - Abstract

Published on Thursday, 09 May 2013 15:35

Testosterone is the major precursor of estradiol (E2) in men.

Association between ipilimumab and celiac disease - Abstract

Published on Wednesday, 08 May 2013 16:24

A 62-year-old man with chemotherapy-naive, castration-resistant metastatic prostate cancer presented with refractory diarrhea despite prolonged high-dose corticosteroid treatment after receiving 3 doses of ipilimumab as part of a phase 3 clinical trial.

AUA 2013 - Session Highlights: AUA Guidelines: Castration Resistant Prostate Cancer

Published on Wednesday, 08 May 2013 13:52

SAN DIEGO, CA USA (UroToday.com) - Michael Cookson, MD, Vice Chair and Professor of Urologic Surgery at Vanderbilt, presented the first AUA guideline for the management of castration-resistant prostate cancer, a lethal form of the disease.

AUA 2013 - Podcast: Michael S. Cookson, MD of Vanderbilt University Medical Center discusses exclusively with UroToday the new AUA guidelines for the treatment of castration-resistant prostate cancer (CRPC)

Published on Wednesday, 08 May 2013 12:08

SAN DIEGO, CA USA (UroToday.com) - In this podcast, Dr. Michael Cookson discusses new treatment options for castration-resistant prostate cancer (CRPC).

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: Results from an open-label, multicenter phase I/II study - Abstract

Published on Tuesday, 07 May 2013 18:41

BACKGROUND: This phase I/II study in patients with metastatic castration-resistant prostate cancer (mCRPC) explored ipilimumab as monotherapy and in combination with radiotherapy, based on the preclinical evidence of synergistic antitumor activity between anti-CTLA-4 antibody and radiotherapy.

Page 1 of 22

Start
Prev
1
2
3
4
5
6
7
8
9
10
Next
End